Mechanisms of action of nebulized low-molecular-weight heparin in patients with bronchial asthma*1

Fal, Andrzej M; Kraus-Filarska, M; Miecielica, Jadwiga; Małolepszy, J

doi:10.1016/j.jaci.2003.12.087

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that inhaled enoxaparin was used just in a pre-post study of 24 asthmatic patients, measuring inflammatory biomarkers, and showed a reduction in eosinophil ( P : 0.006) and lymphocytes of bronchoalveolar lavage without any significant change in IL-5 or Eosinophil Cationic Protein (ECP) concentrations [ 12 ]. Therefore, it seems that enoxaparin could be a valuable add on treatment in asthma like UFH.…”

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review

Mousavi

Moradi

Khorshidahmad

et al. 2015

Advances in Pharmacological Sciences

210

212

View full text Add to dashboard Cite

Background. Heparin, used clinically as an anticoagulant, also has anti-inflammatory properties. The purpose of this systematic review was to provide a comprehensive review regarding the efficacy and safety of heparin and its derivatives as anti-inflammatory agents. Methods. We searched the following databases up to March 2012: Pub Med, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar using combination of Mesh terms. Randomized Clinical Trials (RCTs) and trials with quasi-experimental design in clinical setting published in English were included. Quality assessments of RCTs were performed using Jadad score and Consolidated Standards of Reporting Trials (CONSORT) checklist. Results. A total of 280 relevant studies were reviewed and 57 studies met the inclusion criteria. Among them 48 studies were RCTs. About 65% of articles had score of 3 and higher according to Jadad score. Twelve studies had a quality score > 40% according to CONSORT items. Asthma (n = 7), inflammatory bowel disease (n = 5), cardiopulmonary bypass (n = 8), and cataract surgery (n = 6) were the most studied disease condition. Forty studies use unfractionated heparin (UFH) for intervention; the remaining studies use low molecular weight heparin (LMWH). Conclusion. Despite the conflicting results, heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use of heparin as an anti-inflammatory agent in clinical setting. However, because of the association between inflammation, atherogenesis, thrombogenesis, and cell proliferation, heparin and related compounds with pleiotropic effects may have greater therapeutic efficacy than compounds acting against a single target.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review

Mousavi

Moradi

Khorshidahmad

et al. 2015

Advances in Pharmacological Sciences

210

212

View full text Add to dashboard Cite

show abstract

“…Whilst expression of epithelial CD138 is increased in Crohn's disease and in lupus nephritis, variable findings have been reported in coeliac disease and asthma . Murine models of asthma suggest an inherent deficiency of CD138 leads to unchecked lymphocyte recruitment . Further research is required to explain the significance of this cell surface protein in EoE.…”

Section: Discussionmentioning

confidence: 99%

“…21,26 Murine models of asthma suggest an inherent deficiency of CD138 leads to unchecked lymphocyte recruitment. 31 Further research is required to explain the significance of this cell surface protein in EoE. It is acknowledged that CD138 is also expressed by and even used as a marker for plasma cells (of immediate relevance to EoE, in accordance with the prolific IgG deposition in oesophageal tissue), but that in this case, the expression of this biomarker was diffuse and intense on oesophageal epithelial cells, in common with other gastrointestinal conditions such as Crohn's disease.…”

Section: Ta B L E 1 Characteristics Of the Study Populationmentioning

confidence: 94%

Impact of food challenge on local oesophageal immunophenotype in eosinophilic oesophagitis

Philpott

Lee

Arrington

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

Background Eosinophilic oesophagitis (EoE) is caused by the ingestion of food antigens. Dietary avoidance can result in clinical and histological remission, while food reintroduction can cause recurrence. It is uncertain if food antigen processing and immune activation occurs locally, in the oesophagus. Therefore, we performed a comparative study of the density of cell surface proteins (known to be involved with antigen presentation) on oesophageal tissue prior to, and following food antigen induced disease recurrence. A secondary aim was to consider novel biomarkers. Method Adult patients with a diagnosis of EoE, who had achieved histological remission with an elimination diet (<15 eosinophils per high power field at oesophageal biopsy), and who underwent food challenge with proven recurrence were included. Immunohistochemistry/immunofluorescence for CD1a, CD3, CD28, CD40, CD69, CD80, CD138, CXCR3 and HLA‐DR was performed. Staining intensity of each biomarker (pixels/mm2) was quantified by semi‐automated analysis (Studio‐FL software). Results Fourteen cases of EoE (pre and post food challenge), 6 GORD and 5 healthy controls were included. HLA‐DR, CD3, CD28, CD40 and CD 138 significantly increased with food reintroduction (P = <0.05). CD1a, CD 69, CD 80 and CXCR3 did not measurably change. Conclusion The presence of cell surface proteins typically associated with antigen presentation (following food antigen induced recurrence) suggests immune activation occurs in the oesophagus, and the relative lack of langerhans cells (CD1a) may indicate this cell type is unimportant. The cell surface protein CD 138 increases with disease recurrence, is not elevated in GORD or healthy controls, and has promise as a biomarker.

show abstract

“…The authors reported an increase in the forced expiratory volume in one second (FEV1), which is an assessment of airway obstruction or bronchoconstriction. They also reported a decrease in the percentage of eosinophils and lymphocytes upon bronchoalveolar lavage, which corresponds to a reduction in inflammation [ 35 ]. Another study demonstrated attenuation of post-exercise bronchoconstriction in patients with exercise-induced asthma [ 36 ].…”

Section: Novel Applications Of Heparinmentioning

confidence: 99%

Heparin: Past, Present, and Future

2016

View full text Add to dashboard Cite

Heparin, the most widely used anticoagulant drug in the world today, remains an animal-derived product with the attendant risks of adulteration and contamination. A contamination crisis in 2007–2008 increased the impetus to provide non-animal-derived sources of heparin, produced under cGMP conditions. In addition, recent studies suggest that heparin may have significant antineoplastic activity, separate and distinct from its anticoagulant activity, while other studies indicate a role for heparin in treating inflammation, infertility, and infectious disease. A variety of strategies have been proposed to produce a bioengineered heparin. In this review, we discuss several of these strategies including microbial production, mammalian cell production, and chemoenzymatic modification. We also propose strategies for creating “designer” heparins and heparan-sulfates with various biochemical and physiological properties.

show abstract

Mechanisms of action of nebulized low-molecular-weight heparin in patients with bronchial asthma*1

Cited by 7 publications

References 0 publications

Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review

Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review

Impact of food challenge on local oesophageal immunophenotype in eosinophilic oesophagitis

Heparin: Past, Present, and Future

Contact Info

Product

Resources

About